Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 3
1996 4
1997 3
1998 3
1999 3
2000 2
2001 3
2002 7
2003 4
2004 9
2005 11
2006 15
2007 20
2008 16
2009 20
2010 24
2011 20
2012 27
2013 34
2014 36
2015 32
2016 42
2017 48
2018 54
2019 57
2020 48
2021 60
2022 61
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

597 results
Results by year
Filters applied: . Clear all
Page 1
Spectrum of Fibrotic Lung Diseases.
Wijsenbeek M, Cottin V. Wijsenbeek M, et al. Among authors: cottin v. N Engl J Med. 2020 Sep 3;383(10):958-968. doi: 10.1056/NEJMra2005230. N Engl J Med. 2020. PMID: 32877584 Review. No abstract available.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: cottin v. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Raghu G, et al. Among authors: cottin v. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. Am J Respir Crit Care Med. 2018. PMID: 30168753
Eosinophilic Lung Diseases.
Cottin V. Cottin V. Clin Chest Med. 2016 Sep;37(3):535-56. doi: 10.1016/j.ccm.2016.04.015. Epub 2016 Jun 25. Clin Chest Med. 2016. PMID: 27514599 Review.
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Collard HR, et al. Among authors: cottin v. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Am J Respir Crit Care Med. 2016. PMID: 27299520 Free article. Review.
Drug-induced interstitial lung disease.
Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Spagnolo P, et al. Among authors: cottin v. Eur Respir J. 2022 Oct 27;60(4):2102776. doi: 10.1183/13993003.02776-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35332071 Review.
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. George PM, et al. Among authors: cottin v. Lancet Respir Med. 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. Lancet Respir Med. 2020. PMID: 32890499
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, Wijsenbeek MS, Zoz DF, Voss F, Maher TM; 1305-0013 Trial Investigators. Richeldi L, et al. Among authors: cottin v. N Engl J Med. 2022 Jun 9;386(23):2178-2187. doi: 10.1056/NEJMoa2201737. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569036 Clinical Trial.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. Among authors: cottin v. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
597 results